Matches in Nanopublications for { ?s ?p "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" ?g. }
Showing items 1 to 27 of
27
with 100 items per page.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.